Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Thoracic irradiation with or without levamisole (NSC #177023) in unresectable non-small cell carcinoma of the lung: a phase III randomized trial of the RTOG.
Int J Radiat Oncol Biol Phys
December 1988
Radiation Oncology Center, Mallinckrodt Institute of Radiology, St. Louis, MO 63108.
A total of 285 patients with medically inoperable (RTOG Stage T1-2, N0-1) or unresectable (RTOG Stage T3, N0-1) non-small cell carcinoma of the lung were randomized by the Radiation Therapy Oncology Group (RTOG) to receive radiation therapy (6000 cGy total dose/6 weeks) plus levamisole (2.5 mg/kg twice weekly for 2 years or until tumor progression) or a placebo. One hundred twenty-nine evaluable patients were assigned to placebo and 131 to levamisole.
View Article and Find Full Text PDFHuman lymphocytes were cultured in vitro with multiple concentrations of antigen, mitogen, and allogeneic cells. The addition of levamisole to stimulated cultures in concentrations of 0.03-33 mug/ml significantly amplified the response of lymphocytes to these stimuli with little or no effect on control cultures.
View Article and Find Full Text PDFEffects of levamisole (NSC-177023) and tetramisole (NSC-102063) in experimental tumor systems.
Cancer Chemother Rep
December 1975
Levamisole and tetramisole had no antitumor effect against the following transplantable syngeneic murine tumors: L1210 leukemia, P388 leukemia, B16 melanoma, Madison 109 lung tumor, and Lewis lung carcinoma. In the Lewis lung carcinoma system there was no effect on primary tumor growth, metastasis, or survival. Tetramisole had a variable effect on the growth of rhabdomyosarcomas and the survival of BALB/c mice following intramuscular inoculation of Moloney sarcoma virus.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!